[BioTimes] VPIX Medical Signs MOUs with Samsung Medical Center and Korea University Anam Hospital for Clinical Research and Co-Development of Digital Biopsy Technology

VPIX Medical, a resident company of Seoul Bio Hub, announced that it has signed Memorandums of Understanding (MOUs) with Samsung Medical Center and Korea University Anam Hospital for clinical research and joint development based on its Digital Biopsy technology.

Through these agreements, each hospital will collaborate with VPIX Medical in areas such as the clinical application of digital biopsy, development of precision diagnostic support models, implementation of training programs for medical professionals, and joint research and academic presentations. The hospitals will act as Centers of Excellence (COE), and VPIX Medical will establish a practical clinical collaboration system with them.

VPIX Medical has developed a miniature confocal fluorescence microscope technology called cCeLL, which enables real-time pathological diagnosis through its digital biopsy solution. The technology allows for real-time acquisition of fluorescent tissue images without the need for slide preparation, making it applicable for intraoperative diagnostic support and telepathology.

Currently, a multicenter clinical trial is underway for cCeLL – In vivo, a Class II medical device designed for in vivo use. The new agreements are expected to accelerate the clinical translation and research outcomes of the technology by strengthening institutional partnerships.

VPIX Medical is also pursuing collaborations with Seoul National University Hospital and Seoul Metropolitan Boramae Medical Center, with plans to expand its clinical partnership network. The company was recently selected for the “Global Expansion Acceleration Program” hosted by Seoul Bio Hub, receiving support such as investor meetings and market entry strategy consulting in the United States, further accelerating its push into the U.S. market.

CEO Kyungmin Hwang of VPIX Medical stated, “Digital biopsy is more than just imaging equipment — it is a platform that provides real-time support for clinical decision-making,” adding, “We will continue to collaborate with diverse clinical institutions to evolve this technology into a solution that works at the patient’s side.”

Jinju Choi, Reporter (news@biotimes.co.kr)
BioTimes, June 4, 2025

Health In News, Venture Square, Korea Duty Free News, Startup Today